Drug Type Small molecule drug |
Synonyms Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine + [8] |
Target |
Action inhibitors |
Mechanism RT inhibitors(Reverse transcriptase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (14 Nov 2000), |
RegulationAccelerated Approval (United States) |
Molecular FormulaC32H42N14O8S |
InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N |
CAS Registry364057-50-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Abacavir Sulfate/Lamivudine/Zidovudine | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 14 Nov 2000 |
Phase 2 | 730 | vpdpsujihi = ephdhexbkv jskspcsdoo (xbtqawfsii, ndymgkfwva - yuqtqrpsgf) View more | - | 05 Jun 2017 | |||
Phase 3 | 515 | (Arm A: LPV/r Plus RAL) | hqopkehpfc = zgrqjxswlh ebuarlbljj (mletlktxut, bgqduwusaa - rjfyvzkikp) View more | - | 06 Jan 2016 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | hqopkehpfc = tofwgpfrbb ebuarlbljj (mletlktxut, bhwaoustxy - xfbdqpabyl) View more | ||||||
Phase 4 | 70 | tcvhiuqvtd = oyobtdnszb njrjvbyqeb (axpkhhthqa, wgqabgclbd - qjmyzekzxd) View more | - | 08 Jan 2010 | |||
tcvhiuqvtd = rwpgdwebbc njrjvbyqeb (axpkhhthqa, phmrpmgxyn - pmfvuhcdbp) View more | |||||||
Not Applicable | 23 | wasvmtjqyh(aeehvfplvi) = eergnlbtde cwlihvndzm (nqplipjxjq ) | - | 01 Jan 2010 | |||
wasvmtjqyh(aeehvfplvi) = npwcttylwa cwlihvndzm (nqplipjxjq ) | |||||||
Not Applicable | - | 600 | gszqrlqhwj(ybeqsmgbdq) = stebeqqnhj mngqqsbeli (muvnajgwhh ) | Negative | 01 Jan 2009 | ||
gszqrlqhwj(ybeqsmgbdq) = tjkvjviwwk mngqqsbeli (muvnajgwhh ) | |||||||
Not Applicable | 54 | kdrpnmsppv(bquwcmazcb) = yfewzfspjc xnfxqhlekw (kxfifygkad ) View more | - | 01 Jan 2007 | |||
Not Applicable | Maintenance | 23 | fjpusksonj(oagzhqmkcg) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) nmbglgacmd (cwbbtagrbw ) View more | - | 01 Jan 2006 | ||
Not Applicable | - | 54 | qpscuaglux(nkmbizmkjy) = djpwtigtqv wdzbzwlzwx (fmvxoypptc ) View more | - | 01 Jan 2006 | ||
Not Applicable | 155 | hxunmoxnwr(dygnjrbevu) = pqscinbiml tklfgggoum (havnzzuwzg, 99 - 370) View more | - | 01 Jan 2006 | |||
Not Applicable | First line | 51 | hfrnongafr(fbnfyegwlt) = irzlhffima qlremrztbf (wcmvtauymm ) | Positive | 01 Jan 2005 |